Evidence map›Paper›PMID 35466956›Full record

ArticleJournal of Parkinson's disease2022

Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson's Disease.

Lucy L Gibson, Thomas A Pollak, Amanda Heslegrave, Abdul Hye, Lucia Batzu, Silvia Rota, Dhaval Trivedi, Timothy R Nicholson, Dominic Ffytche, Henrik Zetterberg and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Lucy L GibsonOld Age Psychiatry Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Thomas A PollakNeuropsychiatry Research and Education Group, Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Amanda HeslegraveDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
Abdul HyeOld Age Psychiatry Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Lucia BatzuDepartment of Basic and Clinical Neuroscience, Parkinson Foundation International Centre of Excellence, Kings College Hospital and Kings College London, London, UK.
Silvia RotaDepartment of Basic and Clinical Neuroscience, Parkinson Foundation International Centre of Excellence, Kings College Hospital and Kings College London, London, UK.
Dhaval TrivediDepartment of Basic and Clinical Neuroscience, Parkinson Foundation International Centre of Excellence, Kings College Hospital and Kings College London, London, UK.
Timothy R NicholsonNeuropsychiatry Research and Education Group, Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Dominic FfytcheOld Age Psychiatry Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Henrik ZetterbergDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
K Ray ChaudhuriDepartment of Basic and Clinical Neuroscience, Parkinson Foundation International Centre of Excellence, Kings College Hospital and Kings College London, London, UK.
Dag AarslandOld Age Psychiatry Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
King's College London · GBKing's College Hospital NHS Foundation Trust · GBStavanger University Hospital · NOUniversity College London · GBUniversity of Gothenburg · SE

Funding

Alzheimer's Society 456Wellcome Trust
6 · The paper itself

Abstract

backgroundNeuropsychiatric symptoms are common and important to people with Parkinson's disease (PD), but their etiology is poorly understood. Plasma neurofilament light (NfL) and p-tau181 are biomarkers of neuro-axonal degeneration and tau pathology respectively, which have yet to be explored in association with the affective and psychotic symptoms in PD.

objectiveTo investigate the relationship between plasma NfL and p-tau181 with the affective and psychotic symptoms in PD.

methodsWe assessed the baseline concentration of plasma NfL and p-tau181 in a cohort of 108 patients with PD and 38 healthy controls. A subgroup of patients (n = 63) were assessed annually with clinical measures for up to 7 years. Psychotic symptoms were assessed using the Non-Motor Symptom Scale and affective symptoms were measured in the Hospital Anxiety and Depression Scale.

resultsBaseline plasma NfL was a significant predictor of psychotic symptoms longitudinally across the study adjusted for age, Hoehn and Yahr stage, duration of follow up, duration of disease, baseline levodopa and dopamine agonist medication, and baseline cognition: (OR 8.15 [95% CI 1.40-47.4], p = 0.020). There was no association between NfL concentration and the cumulative prevalence of affective symptoms. Plasma p-tau181 concentration was not associated with psychotic or affective symptoms.

conclusionThese findings suggest psychotic symptoms are associated with greater neurodegeneration in PD. Further studies are needed to explore NfL as a potential biomarker for psychosis in PD.

Indexed as

Parkinson DiseasePsychotic DisordersBiomarkersHumansIntermediate FilamentsNeurofilament ProteinsBiomarkersNeurofilament ProteinsbiomarkerNeurofilament lightneuropsychiatric symptomsParkinson’s diseasepsychosisp-tau

Identifiers

PMID35466956
PMCPMC7616984
OpenAlexW4224264034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.